Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

es in treating resistant bacterial infections, particularly those caused by MRSA. With Phase 3 trial results showing efficacy in only 3 to 7 days of treatment, we believe oritavancin may become part of a new treatment paradigm for infections caused by MRSA and other gram-positive bacteria, and could confer pharmacoeconomic benefits, if approved."

"Despite the introduction of several new antibiotics in the past decade, we continue to see an increase in the development of resistant gram-positive bacteria," said Peter Appelbaum, M.D., Ph.D., professor, division of clinical pathology and medical director, clinical microbiology at Penn State University. "There is an ongoing need for new bactericidal antibiotics that address the limitations of currently marketed therapies. Oritavancin has proven to be very potent in vitro against a broad spectrum of gram-positive organisms resistant to other agents. Also, due to its multiple mechanisms of action, oritavancin may hinder the rapid development of resistance; concordantly, contemporary surveillance studies have shown that oritavancin retains potency against all gram-positive organisms tested. The infectious disease community looks forward to adding a therapy with the characteristics of oritavancin."

More Background on the Market for Novel Antibiotics

There is a growing need for novel antibiotics since bacteria can mutate quickly and often develop resistance to existing antibiotics. Hospital-acquired infections are particularly likely to be resistant to existing antibiotics, but resistance is also growing rapidly in community- acquired infections. As bacteria become more resistant to currently marketed antibiotics, an increasing prevalence of drug-resistant bacterial pathogens can lead to increased mortality rates, prolonged hospitalizations, and increased healthcare costs.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and c
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... ... Sherley says the company is making good progress in evaluating the full range ... adult tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and ...
(Date:7/28/2015)... 2015  PDL BioPharma, Inc. (PDL, or the Company) ... will release its second quarter 2015 financial results for ... 5, 2015, after market close. PDL,s management will host ... p.m. Eastern Time to discuss the financial results.  A ... via the webcast link on the PDL website. ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... the addition of the "Biomedical Refrigerators and ... Growth, Trends and Forecast 2014 - 2022" ... global biomedical refrigerators and freezers market has been ... diagnostic centers, blood banks, and others. The others ...
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... -- Advisor to President Barack Obama for the Office ... visited the Navy,s corporate laboratory, March 16, to dedicate ... (LASR) and tour the sprawling 130-acre Washington, D.C., campus. ... Navy, Marine Corps and our Nation in ever evolving ...
...  Foundation for Health Improvement and Technology (FHIT), ... nonprofit, with the mission to rid the world ... educational programs promoting early detection and aggressive medical ... have made it entirely possible to detect many ...
... 2012More than half of likely voters doubt that the ... in science, technology and health care by the year ... commissioned by Research!America. The findings reveal deep concerns among ... status in innovation, research and development before the next ...
Cached Biology Technology:White House S&T advisor the Honorable Dr. John Holdren tours Naval Research Laboratory 2Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease 2More than half of Americans doubt US global leadership in 2020 2
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... CLEVELAND, Ohio (June 12, 2013)More than half of middle-aged women ... Hispanic women are less likely to have them than white ... high, showed a survey of some 1,500 women published online ... American Menopause Society (NAMS). The survey, conducted by researchers ...
... patent was awarded today to the late Ernest Geskin, PhD, ... a mechanical engineering professor at NJIT for more than 25 ... his former student and now a senior mechanical engineer for ... and Method for Forming of Tubular Parts" discloses a method ...
... study finds that stroke patients, brains show strong cortical motor ... that offers new insight into stroke rehabilitation. Using functional ... monitored the brains of 24 individuals 12 who had ... as they watched others performing actions made using the arm ...
Cached Biology News:Hot flashes before menopause? It can happen 2Patent awarded today to NJIT for novel use of water jets to create high tensile strength alloy parts 2Exercise for stroke patients' brains 2
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Eagle's Ham's amino acids; EHAA...
... provides quick and easy operation of a ... control. The software is fully secure ... CFR Part 11 regulations, and compatible with ... IRsolutions versatility enables use in high-level research ...
... We can introduce random mutations to the gene ... then cloned into a vector of choice to ... Mutation frequency can be set to a desired ... of clones 106-108. Mutations can be restricted ...
Biology Products: